Gilead Sciences Acquires Ouro Medicines to Boost T Cell Engager Program
Gilead Sciences, Inc. has announced a significant acquisition of Ouro Medicines, a biotechnology firm specializing in T cell engager therapies aimed at autoimmune diseases. This move is intended to strengthen Gilead’s inflammation portfolio through the addition of OM336, a clinical-stage bispecific BCMAxCD3 T cell engager.
Acquisition Overview
The deal, valued at approximately $1.675 billion in upfront cash, will also include up to $500 million in contingent milestone payments. Gilead’s acquisition will provide them with exclusive rights to the innovative therapy that has shown promising results in controlling autoimmune diseases.
Significance of OM336
OM336, also known as gamgertamig, is designed to promote significant B cell depletion through a quick, subcutaneous treatment. Initial Phase 1/2 clinical trials suggest that OM336 may offer transformative results with a strong safety profile for conditions like autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). The therapy has received both Fast Track and Orphan Drug Designations from the U.S. FDA.
Future Prospects
Gilead plans to initiate registrational studies for OM336 in 2027, emphasizing the potential for turning points in treatment strategies for severe autoimmune disorders. According to Dr. Dietmar Berger, Chief Medical Officer at Gilead, this acquisition reinforces their dedication to advancing innovative therapies.
Collaboration with Galapagos
Alongside the acquisition, Gilead is in talks with Galapagos to establish a research and development collaboration. Key aspects of this partnership include:
- Galapagos will contribute 50% of the upfront payment and milestone payments.
- They will also manage the operational aspects of Ouro Medicines, retaining its employees.
- Development costs leading to registrational studies will be the responsibility of Galapagos, with shared costs for the studies themselves.
Gilead will hold the global commercialization rights for OM336, except in Greater China, where Keymed Biosciences will retain rights. Royalty agreements between Gilead and Galapagos will offer royalties of 20%-23% of net sales.
Strategic Importance
The introduction of BCMA-targeted T cell engagers could mark a substantial advancement in managing autoimmune diseases. By directing T cells to eliminate pathogenic B cells, therapies like OM336 may foster durable remissions without long-term immunosuppression.
Company Backgrounds
Gilead Sciences has been at the forefront of biopharmaceutical innovation for over 30 years, with operations extending across more than 35 countries. In contrast, Ouro Medicines, founded in 2025, has emerged as a leader in developing immune reset therapies focused on chronic autoimmune diseases.
This acquisition highlights Gilead’s ongoing commitment to improving treatment outcomes through innovative science, ultimately aiming to enhance standards of care in the field of autoimmune disease management.
